Sulaiman Mohammed Al Twijri, Abdulmajeed Alzakari
Manarat Al-Riyadh School, Riyadh, SAUDI ARABIA
Around Twenty thousand people die yearly worldwide because of the systemic lupus erythematousus. One of the reasons that causes this disease is the body`s excessive production of IFN-BETA. The present project aims at finding a novel treatment to cure this disorder using P38 MAPK inhibitor after Lipopolysaccharide cycle on human cells and by measuring the effect of this process on producing five proteins namely: IFN-BETA, TNF-ALPHA, Cox2, Cxcl1 and IL6. The experiment passed through five steps as follows: cell culturing, total RNA preparation, Agarose electrophoresis, RNA quantification (Nanodrop), preparation of cDNA. The experiment was carried out on 18 samples divided into 3 groups: a control group, a group treated with LPS, and a group treated with LPS and the P38 MAPK inhibitor (SB 203580). The results obtained from this experiment show that the P38 MAPK inhibitor (SB 203580) contributes to near elimination of IFN-BETA protein with the percentage of 96.7%. However, the P38 MAPK inhibitor (SB 203580) effect on TNF-ALPHA, Cox2, Cxcl1 and IL6 was not as that of IFN-Beta. This leads to the conclusion that the P38 MAPK inhibitors (SB 203580) cure the excessive IFN-Beta production. As a result, the P38 MAPK inhibitors (SB 203580) can help in treating systemic lupus erythematous us and stop the suffering of many people.